

Nasrin Asgari

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1701516/publications.pdf>

Version: 2024-02-01

71
papers

5,644
citations

168829

31
h-index

90395

73
g-index

73
all docs

73
docs citations

73
times ranked

4149
citing authors

#	ARTICLE	IF	CITATIONS
1	Astrocytic outer retinal layer thinning is not a feature in AQP4-IgG seropositive neuromyelitis optica spectrum disorders. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 188-195.	0.9	13
2	COVID-19 susceptibility and outcomes among patients with neuromyelitis optica spectrum disorder (NMOSD): A systematic review and meta-analysis. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 57, 103359.	0.9	18
3	CSF GFAP levels in double seronegative neuromyelitis optica spectrum disorder: no evidence of astrocyte damage. <i>Journal of Neuroinflammation</i> , 2022, 19, 86.	3.1	13
4	Type I interferon-activated microglia are critical for neuromyelitis optica pathology. <i>Glia</i> , 2021, 69, 943-953.	2.5	11
5	Frequency of comorbidities in Neuromyelitis Optica spectrum disorder. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 48, 102685.	0.9	10
6	An Experimental Model of Neuromyelitis Optica Spectrum Disorder—Optic Neuritis: Insights Into Disease Mechanisms. <i>Frontiers in Neurology</i> , 2021, 12, 703249.	1.1	6
7	The protective effect of Angiotensin AT2-receptor stimulation in Neuromyelitis optica spectrum disorder is independent of astrocyte-derived BDNF. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 53, 103033.	0.9	1
8	Asian and African/Caribbean AQP4-NMOSD patient outcomes according to self-identified race and place of residence. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 53, 103080.	0.9	7
9	Retinal Optical Coherence Tomography in Neuromyelitis Optica. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2021, 8, .	3.1	47
10	Myelin-oligodendrocyte glycoprotein antibody-associated disease. <i>Lancet Neurology</i> , The, 2021, 20, 762-772.	4.9	261
11	Mitochondria—A target for attenuation of astrocyte pathology. <i>Journal of Neuroimmunology</i> , 2021, 358, 577657.	1.1	1
12	Angiotensin AT2 receptor-induced interleukin-10 attenuates neuromyelitis optica spectrum disorder-like pathology. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1187-1196.	1.4	9
13	Protective roles for myeloid cells in neuroinflammation. <i>Scandinavian Journal of Immunology</i> , 2020, 92, e12963.	1.3	15
14	Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: Results from 163 lumbar punctures in 100 adult patients. <i>Journal of Neuroinflammation</i> , 2020, 17, 261.	3.1	84
15	Gender issues of antibody-mediated diseases in neurology: (NMOSD/autoimmune encephalitis/MG). <i>Therapeutic Advances in Neurological Disorders</i> , 2020, 13, 175628642094980.	1.5	23
16	Cohort profile: a collaborative multicentre study of retinal optical coherence tomography in 539 patients with neuromyelitis optica spectrum disorders (CROCTINO). <i>BMJ Open</i> , 2020, 10, e035397.	0.8	10
17	Pre-pregnancy, obstetric and delivery status in women with neuromyelitis optica spectrum disorder. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 44, 102252.	0.9	4
18	Highly sensitive quantification of optic neuritis intrathecal biomarker CXCL13. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 44, 102281.	0.9	3

#	ARTICLE	IF	CITATIONS
19	Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide. <i>Frontiers in Neurology</i> , 2020, 11, 501.	1.1	216
20	Inflammatory profiles relate to survival in subtypes of amyotrophic lateral sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	3.1	30
21	Efficacy and safety of rituximab in patients with refractory neuromyelitis optica spectrum disorders: A prospective observation in Iranian cases. <i>Caspian Journal of Internal Medicine</i> , 2020, 11, 155-162.	0.1	4
22	Epidemiology of neuromyelitis optica spectrum disorder in Denmark (1998â€“2008, 2007â€“2014). <i>Brain and Behavior</i> , 2019, 9, e01338.	1.0	12
23	Vocal cord paralysis as primary and secondary results of malignancy. A prospective descriptive study. <i>Laryngoscope Investigative Otolaryngology</i> , 2019, 4, 241-245.	0.6	4
24	Cerebrospinal fluid biomarkers for predicting development of multiple sclerosis in acute optic neuritis: a population-based prospective cohort study. <i>Journal of Neuroinflammation</i> , 2019, 16, 59.	3.1	39
25	Reader response: Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark. <i>Neurology</i> , 2019, 93, 722-723.	1.5	1
26	Autoimmune diseases associated with Neuromyelitis Optica Spectrum Disorders: A literature review. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 27, 350-363.	0.9	111
27	Long-term tolerability, safety and efficacy of rituximab in neuromyelitis optica spectrum disorder: a prospective study. <i>Journal of Neurology</i> , 2019, 266, 642-650.	1.8	25
28	Disability and Therapeutic Response in Paediatric Neuromyelitis Optica Spectrum Disorder: A Case Series from Iran. <i>Iranian Journal of Child Neurology</i> , 2019, 13, 99-104.	0.2	1
29	A comparison of pediatric and adult neuromyelitis optica spectrum disorders: A review of clinical manifestation, diagnosis, and treatment. <i>Journal of the Neurological Sciences</i> , 2018, 388, 222-231.	0.3	25
30	Environmental risk factors in neuromyelitis optica spectrum disorder: a caseâ€“control study. <i>Acta Neurologica Belgica</i> , 2018, 118, 277-287.	0.5	32
31	Parental ethnicity associated with risk for multiple sclerosis: A population-based incident caseâ€“control study in Iran. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 20, 100-103.	0.9	9
32	Magnetic resonance imaging findings at the first episode of acute optic neuritis. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 20, 30-36.	0.9	23
33	Selective localization of IgG from cerebrospinal fluid to brain parenchyma. <i>Journal of Neuroinflammation</i> , 2018, 15, 110.	3.1	6
34	Autoimmune and immunogenetic profile of patients with optic neuritis in a population-based cohort. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 21, 97-102.	0.9	5
35	Aquaporin-4-autoimmunity in patients with systemic lupus erythematosus: A predominantly population-based study. <i>Multiple Sclerosis Journal</i> , 2018, 24, 331-339.	1.4	45
36	Leptomeningeal and Intraparenchymal Blood Barrier Disruption in a MOG-IgG-Positive Patient. <i>Case Reports in Neurological Medicine</i> , 2018, 2018, 1-3.	0.3	7

#	ARTICLE	IF	CITATIONS
37	Racial differences in neuromyelitis optica spectrum disorder. <i>Neurology</i> , 2018, 91, e2089-e2099.	1.5	140
38	Primary progressive multiple sclerosis in Iran: A consensus recommendation for diagnosis and management. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 26, 112-120.	0.9	5
39	Epidemiology of neuromyelitis optica spectrum disorder. <i>Acta Neurologica Scandinavica</i> , 2018, 137, 626-627.	1.0	1
40	MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. <i>Journal of Neuroinflammation</i> , 2018, 15, 134.	3.1	563
41	Optical coherence tomography in acute optic neuritis: A population-based study. <i>Acta Neurologica Scandinavica</i> , 2018, 138, 566-573.	1.0	44
42	Disruption of the leptomeningeal blood barrier in neuromyelitis optica spectrum disorder. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017, 4, e343.	3.1	55
43	Diagnosis and management of Neuromyelitis Optica Spectrum Disorder (NMOSD) in Iran: A consensus guideline and recommendations. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 18, 144-151.	0.9	33
44	A population-based prospective study of optic neuritis. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1893-1901.	1.4	81
45	Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial. <i>Journal of Neurology</i> , 2017, 264, 2003-2009.	1.8	146
46	Influence of type I IFN signaling on anti-MOG antibody-mediated demyelination. <i>Journal of Neuroinflammation</i> , 2017, 14, 127.	3.1	15
47	MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. <i>Journal of Neuroinflammation</i> , 2016, 13, 279.	3.1	351
48	MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. <i>Journal of Neuroinflammation</i> , 2016, 13, 280.	3.1	686
49	MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients. <i>Journal of Neuroinflammation</i> , 2016, 13, 282.	3.1	217
50	Aquaporin-4 IgG autoimmune syndrome and immunoreactivity associated with thyroid cancer. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e252.	3.1	11
51	MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome. <i>Journal of Neuroinflammation</i> , 2016, 13, 281.	3.1	202
52	Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes. <i>Journal of Neurology</i> , 2016, 263, 140-149.	1.8	60
53	Hypersensitivity Responses in the Central Nervous System. <i>Frontiers in Immunology</i> , 2015, 6, 517.	2.2	7
54	Use of Advanced Magnetic Resonance Imaging Techniques in Neuromyelitis Optica Spectrum Disorder. <i>JAMA Neurology</i> , 2015, 72, 815.	4.5	59

#	ARTICLE	IF	CITATIONS
55	Cerebrospinal fluid aquaporin-4-immunoglobulin G disrupts blood brain barrier. <i>Annals of Clinical and Translational Neurology</i> , 2015, 2, 857-863.	1.7	37
56	Neuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomography. <i>Multiple Sclerosis Journal</i> , 2015, 21, 678-688.	1.4	209
57	Demographic and clinical features of neuromyelitis optica: A review. <i>Multiple Sclerosis Journal</i> , 2015, 21, 845-853.	1.4	278
58	MRI characteristics of neuromyelitis optica spectrum disorder. <i>Neurology</i> , 2015, 84, 1165-1173.	1.5	523
59	Update on biomarkers in neuromyelitis optica. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e134.	3.1	104
60	Pregnancy outcomes in a woman with neuromyelitis optica. <i>Neurology</i> , 2014, 83, 1576-1577.	1.5	20
61	Interferons in the central nervous system: A few instruments play many tunes. <i>Glia</i> , 2014, 62, 339-355.	2.5	99
62	Antibodies against interferon-beta in neuromyelitis optica patients. <i>Journal of the Neurological Sciences</i> , 2014, 339, 52-56.	0.3	5
63	Modifications of longitudinally extensive transverse myelitis and brainstem lesions in the course of neuromyelitis optica (NMO): a population-based, descriptive study. <i>BMC Neurology</i> , 2013, 13, 33.	0.8	84
64	Neuromyelitis optica-like pathology is dependent on type I interferon response. <i>Experimental Neurology</i> , 2013, 247, 744-747.	2.0	23
65	Complement-dependent pathogenicity of brain-specific antibodies in cerebrospinal fluid. <i>Journal of Neuroimmunology</i> , 2013, 254, 76-82.	1.1	38
66	Evolution of longitudinally extensive transverse myelitis in an aquaporin-4 IgG-positive patient. <i>Neurology</i> , 2013, 81, 95-96.	1.5	36
67	Interferon Alpha Association with Neuromyelitis Optica. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-6.	3.3	16
68	Epidemiological, clinical and immunological aspects of neuromyelitis optica (NMO). <i>Danish Medical Journal</i> , 2013, 60, B4730.	0.5	8
69	HLA, PTPN22 and PD-1 associations as markers of autoimmunity in neuromyelitis optica. <i>Multiple Sclerosis Journal</i> , 2012, 18, 23-30.	1.4	50
70	Neuromyelitis optica (NMO) - an autoimmune disease of the central nervous system (CNS). <i>Acta Neurologica Scandinavica</i> , 2011, 123, 369-384.	1.0	31
71	A population-based study of neuromyelitis optica in Caucasians. <i>Neurology</i> , 2011, 76, 1589-1595.	1.5	240